Literature DB >> 8721671

Induction of NF-kB-like transcription factors in brain areas susceptible to kainate toxicity.

I Pérez-Otano1, M K McMillian, J Chen, G Bing, J S Hong, K R Pennypacker.   

Abstract

Administration of kainate (KA), a glutamate receptor agonist, to rats causes neuronal damage in the CA1/CA3 fields of the hippocampus and in the pyriform/ entorhinal cortex. Reactive gliosis also occurs and activated astrocytes upregulate their expression of a large number of molecules. Since NF-kB transcription factors are involved in cellular responses to diverse pathogenic stimuli and have been shown to be induced in astrocytes in vitro in response to cytokines and growth factors, we investigated their possible involvement in the changes in gene expression subsequent to KA-induced lesions. Immunoreactivity to the p65 subunit of NF-kB was markedly increased in non-neuronal cells 2 days after KA administration (8 mg/kg i.p.) in the areas of selective neuronal degeneration. This increase was not observed 3 h or 1 day after injection, but was still present 7-10 days after KA injection. By gel mobility-shift assay, a protein complex binding to the kB consensus sequence was found to be induced by 2 days after KA, which correlated with immunohistochemical findings. This NF-kB-protein complex seemed to be localized in reactive astrocytes, as indicated by the morphological similarity of NF-kB-positive cells and reactive astrocytes stained with glial fibrillary acidic protein (GFAP) antibody, and the parallelism between the time course of NF-kB induction and appearance of gliosis after KA treatment. Double immunocytochemistry experiments demonstrated the colocalization of NF-kB positive cells and reactive astrocytes. Our results suggest that activated NF-kB in astrocytes participates in delayed and long-term responses of glia to injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721671     DOI: 10.1002/(SICI)1098-1136(199604)16:4<306::AID-GLIA3>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  8 in total

1.  Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease.

Authors:  S Hunot; B Brugg; D Ricard; P P Michel; M P Muriel; M Ruberg; B A Faucheux; Y Agid; E C Hirsch
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  Caspase activation contributes to astrogliosis.

Authors:  Radha Aras; Anna M Barron; Christian J Pike
Journal:  Brain Res       Date:  2012-03-01       Impact factor: 3.252

Review 3.  Signaling pathways in reactive astrocytes, a genetic perspective.

Authors:  Wenfei Kang; Jean M Hébert
Journal:  Mol Neurobiol       Date:  2011-01-14       Impact factor: 5.590

4.  A short segment within the cytoplasmic domain of the neural cell adhesion molecule (N-CAM) is essential for N-CAM-induced NF-kappa B activity in astrocytes.

Authors:  E B Little; K L Crossin; L A Krushel; G M Edelman; B A Cunningham
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

5.  Salsolinol, an endogenous neurotoxin, activates JNK and NF-kappaB signaling pathways in human neuroblastoma cells.

Authors:  Sawitri Wanpen; Patcharee Kooncumchoo; Shaik Shavali; Piyarat Govitrapong; Manuchair Ebadi
Journal:  Neurochem Res       Date:  2007-03       Impact factor: 3.996

6.  Age-Dependent Alterations in the Interactions of NF-κB and N-myc with GLT-1/EAAT2 Promoter in the Pericontusional Cortex of Mice Subjected to Traumatic Brain Injury.

Authors:  Rajaneesh K Gupta; S Prasad
Journal:  Mol Neurobiol       Date:  2015-06-17       Impact factor: 5.590

7.  Cautionary notes on the use of NF-κB p65 and p50 antibodies for CNS studies.

Authors:  Miles Herkenham; Priyanka Rathore; Pierre Brown; Samuel J Listwak
Journal:  J Neuroinflammation       Date:  2011-10-14       Impact factor: 8.322

Review 8.  The Function of NF-Kappa B During Epilepsy, a Potential Therapeutic Target.

Authors:  Mengtan Cai; Weihong Lin
Journal:  Front Neurosci       Date:  2022-03-10       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.